Hillhouse Capital Management Ltd. bought a new stake in shares of TESARO, Inc. (NASDAQ:TSRO) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 29,697 shares of the biopharmaceutical company’s stock, valued at approximately $4,153,000. Hillhouse Capital Management Ltd. owned about 0.05% of TESARO at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Botty Investors LLC purchased a new stake in TESARO during the 2nd quarter valued at $140,000. Nordea Investment Management AB purchased a new stake in TESARO during the 2nd quarter valued at $167,000. Meeder Asset Management Inc. purchased a new stake in TESARO during the 1st quarter valued at $177,000. Oppenheimer Asset Management Inc. boosted its stake in TESARO by 3,042.6% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock valued at $206,000 after purchasing an additional 1,430 shares during the last quarter. Finally, BB&T Securities LLC purchased a new stake in TESARO during the 2nd quarter valued at $222,000.

Shares of TESARO, Inc. (NASDAQ TSRO) traded down 2.10% during trading on Thursday, reaching $119.26. The company had a trading volume of 172,486 shares. TESARO, Inc. has a 1-year low of $96.52 and a 1-year high of $192.94. The company’s 50 day moving average is $121.70 and its 200-day moving average is $135.65. The stock’s market capitalization is $6.46 billion.

TESARO (NASDAQ:TSRO) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.52) by ($0.30). The business had revenue of $29.50 million for the quarter, compared to analyst estimates of $18.61 million. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The company’s revenue for the quarter was down 17.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.28) earnings per share. On average, equities research analysts anticipate that TESARO, Inc. will post ($8.59) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/10/05/hillhouse-capital-management-ltd-buys-shares-of-29697-tesaro-inc-tsro.html.

TSRO has been the topic of several recent analyst reports. Citigroup Inc. reiterated a “buy” rating and set a $216.00 target price on shares of TESARO in a research note on Monday, September 11th. Robert W. Baird reiterated a “neutral” rating and set a $140.00 target price (down from $155.00) on shares of TESARO in a research note on Thursday, August 10th. Cowen and Company cut their target price on TESARO from $145.00 to $124.00 and set a “market perform” rating on the stock in a research note on Monday, June 19th. Credit Suisse Group set a $190.00 target price on TESARO and gave the company a “buy” rating in a research note on Friday, August 18th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $183.00 target price on shares of TESARO in a research note on Thursday, August 10th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. TESARO currently has an average rating of “Buy” and an average target price of $170.74.

In other TESARO news, VP Grant C. Bogle sold 14,167 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $135.00, for a total value of $1,912,545.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Martin H. Jr. Huber sold 592 shares of the company’s stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $118.60, for a total transaction of $70,211.20. Following the completion of the transaction, the senior vice president now owns 6,943 shares of the company’s stock, valued at approximately $823,439.80. The disclosure for this sale can be found here. Insiders have sold 35,692 shares of company stock valued at $4,628,976 over the last 90 days. 40.50% of the stock is currently owned by insiders.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO, Inc. (NASDAQ:TSRO).

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.